SubHero Banner

Biaxin®/Biaxin® XL (clarithromycin) – New warning

June 9, 2017 – The FDA approved an update to the Warnings and Precautions section of the Biaxin/Biaxin XL (clarithromycin) drug label regarding the risk of all-cause mortality one year or more after the end of treatment in patients with coronary artery disease (CAD).

Download PDF